Abbott ACT I Carotid Stent Clinical Trial

Abbott Vascular ACT I is a prospective, randomized, multi-center trial that is enrolling a maximum of 1,658  patients, at up to 50 sites in North America.

ACT I is designed to demonstrate the non-inferiority of CAS when compared to carotid endarterectomy (CEA) for the treatment of asymptomatic carotid artery disease (CAD) in people at normal risk for surgery.

ACT I is using Abbott Vascular Emboshield BareWire Rapid Exchange Embolic Protection System with the Xact Rapid Exchange Carotid Stent System.